BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
1.970
-0.040 (-1.99%)
At close: Oct 8, 2025, 4:00 PM EDT
1.970
0.00 (0.00%)
After-hours: Oct 8, 2025, 4:00 PM EDT
BioVie Employees
BioVie had 13 employees as of June 30, 2025. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$1,377,814
Market Cap
14.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 13 | -1 | -7.14% |
| Jun 30, 2024 | 14 | -4 | -22.22% |
| Jun 30, 2023 | 18 | 5 | 38.46% |
| Jun 30, 2022 | 13 | 7 | 116.67% |
| Jun 30, 2021 | 6 | 2 | 50.00% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BIVI News
- 12 days ago - BioVie to Host Live Investor Webinar and Q&A on Oct. 8 - GlobeNewsWire
- 2 months ago - BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes - GlobeNewsWire
- 2 months ago - BioVie Inc. Announces Pricing of $12 Million Public Offering - GlobeNewsWire
- 2 months ago - BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology - GlobeNewsWire
- 2 months ago - BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors - GlobeNewsWire
- 3 months ago - BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD) - GlobeNewsWire
- 3 months ago - BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress - GlobeNewsWire
- 5 months ago - BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 - GlobeNewsWire